Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RIBOCANCER

Financiado

Cerrado

Ribosome defects in cancer

"Cancer cells are defective in vital cell functions such as cell cycle control and response to growth signals. We found that cancer cells acquire defects in yet another vital function: translation of mRNA into proteins. We saw tha... ver más

31/12/2018

KU Leuven

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-12-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

KU Leuven

0.00€ | Lider

VLAAMS INSTITUUT BIOTECHNOL...

N.D. | Participante

Proyectos interesantes

SAF2014-52162-P

Medical Technol...

Applied Physics

424K€ Cerrado

SAF2017-84301-P

Medical Technol...

Applied Physics

339K€ Cerrado

PID2021-122125NB-I00

Medical Technol...

Applied Physics

254K€ Cerrado

RiboID

Medical Technol...

Applied Physics

2M€ Cerrado

TMP53COMPMIX

Medical Technol...

Applied Physics

100K€ Cerrado

DBA-CHECKPOINTS

Medical Technol...

Applied Physics

100K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Cancer cells are defective in vital cell functions such as cell cycle control and response to growth signals. We found that cancer cells acquire defects in yet another vital function: translation of mRNA into proteins. We saw that 9.8% of children with T-cell leukemia (T-ALL) harbor acquired mutations in the ribosome, the cellular protein translation factory. We found mutations in RPL10, RPL5 and RPL22, 3 proteins of the large 60S ribosomal subunit. Strikingly, 6.5% of T-ALL patients had the same RPL10 R98S missense mutation. Although congenital ribosome defects were previously linked to higher cancer risk, the concept that defects in the ribosome are acquired during life and are selected for in cancer is novel. In addition, it is currently not understood by what mechanism ribosome defects are carcinogenic. Patients with inherited ribosome defects are predisposed to all types of cancer. Therefore, other cancers than T-ALL may show acquired defects in the ribosome and I want to explore the prevalence of acquired ribosome defects in various cancer types. Second, I want to explore by which mechanism ribosome mutations promote cancer. Initially, I will focus on the RPL10 R98S mutation, the most frequent acquired ribosome defect we found so far. We will test the effect of RPL10 R98S on cell behavior parameters such as self-renewal capacity and resistance to apoptosis. I hypothesize that altered translation of a subset of cellular mRNAs, including mRNAs coding major tumor suppressors or oncogenes, may explain the oncogenic action of RPL10 R98S. Therefore, we will identify all mRNAs with altered translation efficiency or fidelity in RPL10 R98S cells. In addition, we will test if RPL10 R98S promotes cancer by altering extra-ribosomal roles of RPL10 or by driving inactivation of the TP53 pathway. Finally, acquired ribosome defects may represent a novel target for cancer therapy and we will test if ribosome defective cancer cells are hypersensitive to translation inhibitors."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores